In this Innovation Showcase talk from ISSCR 2020 Virtual, Amanda Fentiman, Hematology Product Manager, gives a detailed overview of CRISPR-mediated genome editing of CD34+ cells in optimized, serum-free, in vitro culture conditions.

The ability to genetically manipulate hematopoietic stem and progenitor cells (HSPCs) can facilitate gains in our understanding of the mechanisms that regulate hematopoiesis and contribute to the development of novel cellular therapies. Optimal culture conditions are key to maintaining the viability, proliferation and differentiation potential of HSPCs and achieve high editing efficiencies in genome editing experiments. In this presentation, Amanda discusses STEMCELL’s products for in vitro expansion of primary human hematopoietic cells, including primitive stem and progenitor cell populations. She also outlines an optimized protocol for gene editing of cord blood-derived CD34+ cells and discusses STEMCELL’s new cGMP animal component-free StemSpan™ medium, manufactured to relevant 21 CFR Part 820 guidelines.

As a supporter of, and participant in, ISSCR’s 2020 Annual Meeting, we share with you our Innovation Showcase presentation at #ISSCR2020.
This presentation does not represent an endorsement from or support of the ISSCR.